Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rapid Mycoplasma Detection Techniques for Facilitating Quality in Low-Volume T-Cell Therapies: Poster presented at PDA Microbiology Conference 2025.

PDA journal of pharmaceutical science and technology·2026

Same author

Four Decades of Cytochrome P450 2B Research: From Protein Adducts to Protein Structures and Beyond.

Drug metabolism and disposition: the biological fate of chemicals·2022

Same author

The Evolution of <i>Drug Metabolism and Disposition</i>: A Perspective From the Editors.

Drug metabolism and disposition: the biological fate of chemicals·2022

Same author

Bringing Big Data to Bear in Environmental Public Health: Challenges and Recommendations.

Frontiers in artificial intelligence·2020

Same author

Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids.

Toxicological sciences : an official journal of the Society of Toxicology·2020

Same author

Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans.

Toxicological sciences : an official journal of the Society of Toxicology·2019

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Developmental changes in human liver CYP2D6 expression.

Jeffrey C Stevens¹, Sandra A Marsh, Matthew J Zaya

¹Pfizer Corporation, Global Research and Development, Chesterfield, Missouri, USA.

Drug Metabolism and Disposition: the Biological Fate of Chemicals

|May 14, 2008

Summary

This summary is machine-generated.

This study reveals that cytochrome P450 2D6 (CYP2D6) expression in pediatric livers changes significantly with age and genetics. These factors influence drug metabolism during development.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Area of Science:

Pharmacology
Genetics
Developmental Biology

Background:

Cytochrome P450 enzymes, including CYP2D6, play a crucial role in drug metabolism.
Developmental expression patterns of drug-metabolizing enzymes can impact drug efficacy and safety in pediatric populations.

Purpose of the Study:

To investigate the developmental expression patterns of CYP2D6 in pediatric liver samples.
To correlate CYP2D6 activity with protein levels and identify factors influencing its expression during development.

Main Methods:

Dextromethorphan O-demethylase activity assays were performed on 222 pediatric liver samples.
Quantitative Western blotting was used to measure CYP2D6 protein levels.
Analysis included correlations with age, gestational age, gender, ethnicity, postmortem interval, and genotype.

Main Results:

CYP2D6 protein levels correlated significantly with enzyme activity across all age groups.
In prenatal samples, only gestational age influenced CYP2D6 expression.
In postnatal samples, both age and genetic factors were associated with CYP2D6 expression, with significantly higher levels observed after 7 days of age and in Caucasian individuals.
CYP2D6 activity was higher in individuals predicted to be extensive or intermediate metabolizers compared to poor metabolizers.

Conclusions:

Age and genetic factors are key determinants of CYP2D6 expression variability in pediatric livers.
Understanding these developmental changes is critical for optimizing drug therapy in children.